annually.42 A landmark study in ambulatory patients in the USA found that every $1 spent on a drug, $1.13 was also being spent due to an ADR. 43, 44 Sparse data exists about the cost of adverse drug reactions in the ambulatory setting. One retrospective cohort study measured an increase in cost after an event at $1,310 for all adverse drug reactions and $1983 for preventable events.45 Most of the figures come from models and simulations rather than direct measurement.37, 46, 47 In a developing country like India, the coverage of insurance policies are limited and thus increasing out of pocket medical expenses resulting in economic burden.
Adverse drug reactions are common among elderly outpatients.
They have important consequences, and one – third of such events are preventable or ameliorable. Improvements in monitoring for and responding to symptoms appear to be especially important for the prevention of ADRs in this setting. In addition, improved communication between ambulatory care patients and their physicians may reduce the frequency of these events. It is clear that ADRs are a source of economic burden on patients, their care – givers and the health care systems that treat them. The majority of the ADRs are mild, however, in some untoward incidents these might be severe, life threatening and/ or fatal. Therefore, through pharmacovigilance (PV) activities, spontaneous reporting of ADRs and conducting observational studies are important tools for detection, assessment and prevention of ADRs, therefore reducing the financial burden of these
ADRs.